 Connection
Benjamin Bitler to Disease Progression
This is a "connection" page, showing publications Benjamin Bitler has written about Disease Progression.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.254 |
|
|
|
-
Watson ZL, Yamamoto TM, McMellen A, Kim H, Hughes CJ, Wheeler LJ, Post MD, Behbakht K, Bitler BG. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma. Clin Epigenetics. 2019 11 27; 11(1):165.
Score: 0.105
-
Bitler BG, Menzl I, Huerta CL, Sands B, Knowlton W, Chang A, Schroeder JA. Intracellular MUC1 peptides inhibit cancer progression. Clin Cancer Res. 2009 Jan 01; 15(1):100-9.
Score: 0.049
-
McMellen A, Woodruff ER, Corr BR, Bitler BG, Moroney MR. Wnt Signaling in Gynecologic Malignancies. Int J Mol Sci. 2020 Jun 16; 21(12).
Score: 0.027
-
Gordon MA, Babbs B, Cochrane DR, Bitler BG, Richer JK. The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing. Mol Carcinog. 2019 02; 58(2):196-205.
Score: 0.024
-
Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG, Allegrezza MJ, Yokoyama Y, Kossenkov AV, Bradner JE, Conejo-Garcia JR, Zhang R. BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. Cell Rep. 2016 09 13; 16(11):2829-2837.
Score: 0.021
-
Horm TM, Bitler BG, Broka DM, Louderbough JM, Schroeder JA. MUC1 drives c-Met-dependent migration and scattering. Mol Cancer Res. 2012 Dec; 10(12):1544-54.
Score: 0.016
-
Pochampalli MR, Bitler BG, Schroeder JA. Transforming growth factor alpha dependent cancer progression is modulated by Muc1. Cancer Res. 2007 Jul 15; 67(14):6591-8.
Score: 0.011
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|